118 related articles for article (PubMed ID: 38181691)
21. Cabazitaxel-loaded poly(alkyl cyanoacrylate) nanoparticles: toxicity and changes in the proteome of breast, colon and prostate cancer cells.
Øverbye A; Torgersen ML; Sønstevold T; Iversen TG; Mørch Ý; Skotland T; Sandvig K
Nanotoxicology; 2021 Sep; 15(7):865-884. PubMed ID: 34047629
[TBL] [Abstract][Full Text] [Related]
22. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain.
Gdowski AS; Ranjan A; Sarker MR; Vishwanatha JK
Nanomedicine (Lond); 2017 Sep; 12(17):2083-2095. PubMed ID: 28805551
[TBL] [Abstract][Full Text] [Related]
23. Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells.
Chen M; Zhou B; Zhong P; Rajamanickam V; Dai X; Karvannan K; Zhou H; Zhang X; Liang G
Prostate; 2017 Apr; 77(5):489-504. PubMed ID: 27990666
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
Luo Y; Ling Y; Guo W; Pang J; Liu W; Fang Y; Wen X; Wei K; Gao X
J Control Release; 2010 Oct; 147(2):278-88. PubMed ID: 20655966
[TBL] [Abstract][Full Text] [Related]
25. Targeted Delivery of Cabazitaxel by Conjugation to Albumin-PEG-folate Nanoparticles Using a Cysteine-acrylate Linker and Simple Synthesis Conditions.
Khoeeniha MK; Esfandyari-Manesh M; Behrouz H; Amini M; Varnamkhasti BS; Atyabi F; Dinarvand R
Curr Drug Deliv; 2017; 14(8):1120-1129. PubMed ID: 27875950
[TBL] [Abstract][Full Text] [Related]
26. Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
Mukhtar E; Adhami VM; Siddiqui IA; Verma AK; Mukhtar H
Mol Cancer Ther; 2016 Dec; 15(12):2863-2874. PubMed ID: 27765854
[TBL] [Abstract][Full Text] [Related]
27. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
28. Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening.
Hongo H; Kosaka T; Suzuki Y; Oya M
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):59-66. PubMed ID: 34593983
[TBL] [Abstract][Full Text] [Related]
29. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells.
Zhang S; Wang Y; Chen Z; Kim S; Iqbal S; Chi A; Ritenour C; Wang YA; Kucuk O; Wu D
Prostate; 2013 Nov; 73(15):1681-9. PubMed ID: 23999913
[TBL] [Abstract][Full Text] [Related]
30. STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
Rocha SM; Nascimento D; Coelho RS; Cardoso AM; Passarinha LA; Socorro S; Maia CJ
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047621
[TBL] [Abstract][Full Text] [Related]
31. Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways.
Ward AB; Mir H; Kapur N; Gales DN; Carriere PP; Singh S
World J Surg Oncol; 2018 Jun; 16(1):108. PubMed ID: 29898731
[TBL] [Abstract][Full Text] [Related]
32. Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways.
Hongo H; Kosaka T; Suzuki Y; Mikami S; Fukada J; Oya M
Sci Rep; 2021 Nov; 11(1):22284. PubMed ID: 34782700
[TBL] [Abstract][Full Text] [Related]
33. Novel T7-Modified pH-Responsive Targeted Nanosystem for Co-Delivery of Docetaxel and Curcumin in the Treatment of Esophageal Cancer.
Deng L; Zhu X; Yu Z; Li Y; Qin L; Liu Z; Feng L; Guo R; Zheng Y
Int J Nanomedicine; 2020; 15():7745-7762. PubMed ID: 33116498
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
[TBL] [Abstract][Full Text] [Related]
35. Reactivation of latent tuberculosis infection induced by cabazitaxel in a patient with prostate cancer: A case report.
Hashimoto M; Minami T; Hamaguchi M; Fujimoto S; Takahashi T; Kikuchi T; Adomi S; Banno E; Ohzeki T; Shimizu N; Mori Y; Nozawa M; Nose K; Yoshimura K; Uemura H
Medicine (Baltimore); 2019 Dec; 98(51):e18436. PubMed ID: 31861013
[TBL] [Abstract][Full Text] [Related]
36. The Andrographolide Analogue 3A.1 Synergizes with Taxane Derivatives in Aggressive Metastatic Prostate Cancers by Upregulation of Heat Shock Proteins and Downregulation of MAT2A-Mediated Cell Migration and Invasion.
Mitra Ghosh T; Kansom T; Mazumder S; Davis J; Alnaim AS; Jasper SL; Zhang C; Bird A; Opanasopit P; Mitra AK; Arnold RD
J Pharmacol Exp Ther; 2022 Mar; 380(3):180-201. PubMed ID: 34949650
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
Zhang S; Gera L; Mamouni K; Li X; Chen Z; Kucuk O; Wu D
Oncotarget; 2016 May; 7(19):27489-98. PubMed ID: 27050371
[TBL] [Abstract][Full Text] [Related]
38. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
Aranha O; Grignon R; Fernandes N; McDonnell TJ; Wood DP; Sarkar FH
Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
[TBL] [Abstract][Full Text] [Related]
39. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
Heidenreich A; Scholz HJ; Rogenhofer S; Arsov C; Retz M; Müller SC; Albers P; Gschwend J; Wirth M; Steiner U; Miller K; Heinrich E; Trojan L; Volkmer B; Honecker F; Bokemeyer C; Keck B; Otremba B; Ecstein-Fraisse E; Pfister D
Eur Urol; 2013 Jun; 63(6):977-82. PubMed ID: 23116658
[TBL] [Abstract][Full Text] [Related]
40. Photodynamic therapy of prostate cancer using porphyrinic formulations.
Mesquita MQ; Ferreira AR; Neves MDGPMS; Ribeiro D; Fardilha M; Faustino MAF
J Photochem Photobiol B; 2021 Oct; 223():112301. PubMed ID: 34492530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
